



I, Karen Lee, hereby certify that I am competent to translate from Chinese to English and that the attached translation is, to the best of my knowledge and belief, a true and accurate translation of the following document from Chinese to English.

Excerpt from Ex. 2017 - Bio-Thera Solutions, Ltd. 2020 Annual Report (Chinese)

A handwritten signature in black ink, appearing to be 'K. Lee'.

Karen Lee

Sworn to before me this
June 15, 2026

A handwritten signature in black ink, appearing to be 'M. Lezhnev'.

Signature, Notary Public

Mikhail E. Lezhnev
Notary Public ID No. 02LE0003393
State of New York Qualified in Kings County
Commission Expires on March 22, 2027

Stamp, Notary Public

Accord BioPharma, Inc.
Exhibit 1095
Accord v. Janssen
IPR2026-00256, -00257, -00258, -00259
Ex. 1095-001

Janssen Biotech, Inc.
Exhibit 2017
Accord v. Janssen
IPR2026-00257

LANGUAGE AND TECHNOLOGY SOLUTIONS FOR GLOBAL BUSINESS

1250 BROADWAY, 7TH FLOOR, NEW YORK, NY 10001 | T 212.689.5555 | F 212.689.1059 | WWW.TRANSPERFECT.COM
OFFICES IN 92 CITIES WORLDWIDE

Company Code: 688177

Company Abbreviation: Bio-Thera

Bio-Thera Solutions, Ltd. 2020 Annual Report



Contents

Section I	Definitions.....	6
Section II	Company Profile and Key Financial Indicators.....	10
Section III	Summary of Company Business.....	16
Section IV	Significant Events	53
Section V	Changes in Shares and Shareholder Information.....	91
Section VI	Preferred Share Information	106
Section VII	Directors, Supervisors, Senior Management Personnel, and Employees.....	107
Section VIII	Corporate Governance.....	117
Section IX	Information Relating to Corporate Bonds	121
Section X	Financial Report	122
Section XI	Documents Available for Inspection	234

II. Securities issuance and listing**(I) Securities issuance during the reporting period**

√ Applicable □ Not Applicable

					Unit: shares	Currency: RMB
Type of stock and derivative securities	Issue date	Issue price (or interest rate)	Number issued	Listing date	Number approved for trading	Trading termination date
Ordinary shares						
A Shares	2020-02-21	RMB 32.76/share	60,000,000	2020-02-21	60,000,000	/

Explanation of securities issuance during the reporting period (for bonds with different interest rates during their term, please describe separately):

√ Applicable □ Not Applicable

Approved by the STAR Market Listing Committee of the Shanghai Stock Exchange on November 20, 2019, and registered pursuant to the Approval for the Registration of the Initial Public Offering of Shares by Bio-Thera Solutions, Ltd. (CSRC Permit [2020] No. 92) issued by the China Securities Regulatory Commission on January 14, 2020, Bio-Thera Solutions, Ltd. was approved to publicly issue 60,000,000 RMB ordinary shares and was listed on the STAR Market of the Shanghai Stock Exchange on February 21, 2020. Following the issuance, the total share capital was 414,080,000 shares.

(II) Changes in the total number of ordinary shares and shareholder structure of the Company, and changes in the Company's asset and liability structure

√ Applicable □ Not Applicable

Before this issuance, the Company had a total share capital of 354.08 million shares. Through this issuance of 60 million RMB ordinary shares, the Company's total share capital increased to 414,080,000 shares. At the beginning of the reporting period, total assets were RMB 1,014.3557 million, total liabilities were RMB 383.6839 million, and the asset-liability ratio was 37.83%; at the end of the reporting period, total assets were RMB 2,393.1598 million, total liabilities were RMB 387.5496 million, and the asset-liability ratio was 16.19%.

III. Shareholders and actual controllers**(I) Total number of shareholders**

Total number of ordinary shareholders as of the end of the reporting period (accounts)	12,889
Total number of ordinary shareholders as of the end of the month preceding the disclosure date of the annual report (accounts)	12,208
Total number of preferred shareholders with restored voting rights as of the end of the reporting period (accounts)	0
Total number of preferred shareholders with restored voting rights as of the end of the month preceding the disclosure date of the annual report (accounts)	0

Number of depositary receipt holders

□ Applicable √ Not Applicable

(II) Shareholdings of the top ten shareholders and top ten circulating shareholders (or shareholders without selling restrictions) as of the end of the reporting period

Unit: shares

Shareholdings of the top ten shareholders								
Name of shareholder (Full name)	Increase/decrease during the reporting period	Number of shares held at the end of the period	Percentage (%)	Number of restricted shares held	Number of restricted shares including shares lent through securities lending and refinancing	Pledged or frozen shares		Nature of shareholder
						Status of shares	Quantity	
Guangzhou Qixi Group Co., Ltd.	0	159,990,270	38.64	159,990,270	0	None	0	Domestic non-state-owned legal person
Therabio International Limited	0	47,177,729	11.39	47,177,729	0	None	0	Overseas legal person
Guangzhou Qiao Xing Investment Partnership (Limited Partnership)	0	23,173,326	5.6	23,173,326	0	None	0	Domestic non-state-owned legal person
Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership (Limited Partnership)	0	21,559,471	5.21	21,559,471	0	None	0	Domestic non-state-owned legal person
Guangzhou CAS Yuechuang Incubator Investment Management Co., Ltd. – Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership)	0	21,333,332	5.15	21,333,332	0	None	0	Domestic non-state-owned legal person
Guangzhou Xingyu Investment Partnership (Limited Partnership)	0	21,320,002	5.15	21,320,002	0	None	0	Domestic non-state-owned legal person

Guangzhou Shengyu Investment Partnership (Limited Partnership)	0	16,000,000	3.86	16,000,000	0	None	0	Domestic non-state-owned legal person
Guangzhou Yichen Investment Enterprise (Limited Partnership)	0	10,744,802	2.59	10,744,802	0	None	0	Domestic non-state-owned legal person
Guangzhou Fanwanhu Investment Partnership (Limited Partnership)	0	7,424,586	1.79	7,424,586	0	None	0	Domestic non-state-owned legal person
SHENGFENG LI	0	6,517,332	1.57	6,517,332	0	None	0	Overseas natural person

Shareholdings of the top ten shareholders without selling restrictions

Name of shareholder	Number of unrestricted circulating shares held	Type and quantity of shares	
		Type	Quantity
Li Xiaofeng	1,269,285	RMB ordinary shares	1,269,285
China International Capital Corporation Hong Kong Asset Management Limited – Client Funds	714,105	RMB ordinary shares	714,105
Ma Jun	442,614	RMB ordinary shares	442,614
China CICC Wealth Securities Co., Ltd.	433,090	RMB ordinary shares	433,090
Huitianze Investment Co., Ltd.	379,118	RMB ordinary shares	379,118
CMS Asset Management – Zhao Zhihong – CMS Asset Management Zhenxiang Value No. 66 Single Asset Management Plan	350,000	RMB ordinary shares	350,000
Cao Yanjun	347,148	RMB ordinary shares	347,148
Shenzhen Qianhai Jiexiang Investment Consulting Co., Ltd.	263,059	RMB ordinary shares	263,059
Liu Zhigang	230,251	RMB ordinary shares	230,251
Ding Tongyin	219,534	RMB ordinary shares	219,534

Explanation of related-party relationships or acting-in-concert relationships among the above shareholders	1.Related-party relationships: (1) Qixi Group is ultimately controlled by the actual controllers Yi Xianzhong, Guan Yuchan, and Yi Liangyu; (2) the general partner and executive partner of Xingyu Investment is Yi Liangyu and is ultimately controlled by Yi Liangyu; (3) The general partner and executive partner of Qiao Xing is Guan Yuchan and is ultimately controlled by Guan Yuchan; (4) Qixi Group holds a 74% limited partnership interest in Yuechuang No. 3, and Yuechuang Incubator, in which Guan Yuchan holds a 55% interest, is the general partner of Yuechuang No. 3; (5) The general partner and executive partner of Shengyu Investment is Yi Xianzhong and is ultimately controlled by Yi Xianzhong; (6) The general partner and executive partner of CAS Zhuochuang is Yuechuang Incubator, in which Guan Yuchan holds a 55% interest, and is ultimately controlled by Guan Yuchan. (7) Therabio International is a company 100% owned by LI SHENGFENG; (8) Fanwanhu is a limited partnership in which LI SHENGFENG and his children hold 100% of the capital contributions, and LI SHENGFENG serves as the general partner and executive partner. (9) Jifu Qiheng's general partner and executive partner, Jifu Venture Capital Co., Ltd., directly and indirectly holds 100% of the capital contributions in Hefei Jiqiang Equity Investment Management Partnership (Limited Partnership), the general partner and executive partner of Hefei Qixing; (10) Dong Zhengqing, the controlling shareholder of Huitianze (holding 98.8% of Huitianze's equity), is also the largest shareholder of Jifu Venture Capital Co., Ltd. (holding 28.3195% of its shares); (11) Huitianze is also the largest shareholder of Huizhifu (holding 38.92% of its equity). 2.Persons acting in concert (1) Controlling shareholder Qixi Group and its persons acting in concert:Guangzhou Qiao Xing Investment Partnership (Limited Partnership), Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership), Guangzhou Xingyu Investment Partnership (Limited Partnership), Guangzhou Shengyu Investment Partnership (Limited Partnership), and Hengqin CAS Zhuochuang Equity Investment Fund Partnership (Limited Partnership); (2) Therabio International Limited and its persons acting in concert: LI SHENGFENG and Guangzhou Fanwanhu Investment Partnership (Limited Partnership); (3) Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership (Limited Partnership) and its persons acting in concert: Hefei Qixing Equity Investment Partnership (Limited Partnership), Huitianze Investment Co., Ltd., and Anhui Huizhifu Venture Capital Co., Ltd.
Explanation of preferred shareholders with restored voting rights and the number of shares held	Not applicable

Number of shares held and selling restrictions applicable to the top ten shareholders holding restricted shares

√ Applicable □ Not Applicable

Unit: shares

No.	Name of shareholder holding restricted shares	Number of restricted shares held	Trading status of restricted shares		Restriction conditions
			Date tradable	Number of newly tradable shares	
1	Guangzhou Qixi Group Co., Ltd.	159,990,270	2023-2-21	0	36 months
2	Therabio International Limited	47,177,729	2023-2-21	0	12 months (prior to the Company achieving profitability, no reduction of pre-IPO shares during the three full fiscal years commencing from the date of listing of the Company's shares); the lock-up release date shall be the earlier of February 21, 2023 or the date the Company achieves profitability.
3	Guangzhou Qiao Xing Investment Partnership	23,173,326	2023-2-21	0	36 months
4	Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership	21,559,471	2021-2-21; 2022-3-28	0	The 2,400,000 shares acquired through a capital increase within six months prior to the filing for the IPO and listing shall not be transferred within 36 months from March 26, 2019, i.e., the lock-up release date is March 28, 2022; the remaining 19,159,471 shares were released from lock-up on February 22, 2021.
5	Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership	21,333,332	2023-2-21	0	36 months
6	Guangzhou Xingyu Investment Partnership	21,320,002	2023-2-21	0	36 months
7	Guangzhou Shengyu Investment Partnership	16,000,000	2023-2-21	0	36 months

8	Guangzhou Yichen Investment Enterprise	10,744,802	2021-2-21; 2022-3-28	0	The 1,000,000 shares acquired through a capital increase within six months prior to the filing for the IPO and listing shall not be transferred within 36 months from March 26, 2019, i.e., the lock-up release date is March 28, 2022; the remaining 9,744,802 shares were released from lock-up on February 22, 2021.
9	Guangzhou Fanwanhu Investment Partnership	7,424,586	2023-2-21	0	12 months (prior to the Company achieving profitability, no reduction of pre-IPO shares during the three full fiscal years commencing from the date of listing of the Company's shares); the lock-up release date shall be the earlier of February 21, 2023 or the date the Company achieves profitability.
10	LI SHENGFENG (Li Shengfeng)	6,517,332	2023-2-21	0	12 months (prior to the Company achieving profitability, no reduction of pre-IPO shares during the three full fiscal years commencing from the date of listing of the Company's shares); the lock-up release date shall be the earlier of February 21, 2023 or the date the Company achieves profitability.
Explanation of related-party relationships or acting-in-concert relationships among the above shareholders		See "Section VI. Changes in Shares and Shareholder Information," "III. Shareholders and Actual Controllers," "(II) Shareholdings of the Top Ten Shareholders and Top Ten Circulating Shareholders (or Shareholders Without Selling Restrictions) as of the End of the Reporting Period" above.			

Table of the Company's top ten domestic depositary receipt holders as of the end of the reporting period

☐ Applicable ☒ Not Applicable

Number of holdings and restriction conditions of the top ten holders of restricted depositary receipts

☐ Applicable ☒ Not Applicable

(III) Table of the top ten shareholders by voting rights as of the end of the reporting period

☐ Applicable ☒ Not Applicable

(IV) Strategic investors or general legal persons becoming top ten shareholders due to allotment of new shares/depositary receipts

☐ Applicable ☒ Not Applicable